<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02152124</url>
  </required_header>
  <id_info>
    <org_study_id>EC/2013/857</org_study_id>
    <secondary_id>WI182140</secondary_id>
    <nct_id>NCT02152124</nct_id>
  </id_info>
  <brief_title>Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?</brief_title>
  <official_title>Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acromegaly is a rare hormonal disorder leading to increased morbidity and mortality. In the
      vast majority of cases, a pituitary somatotroph cell adenoma causes excess growth hormone
      (GH) secretion, leading to hepatic insulin-like-growth factor 1 (IGF-1) hypersecretion. Both
      the disease as well as its treatment with long-acting somatostatin analogs (LA-SMSA) and/or
      pegvisomant affect glucose and lipid metabolism, possibly contributing to increased
      cardiovascular risk.

      In this pilot study, the investigators want to explore insulin sensitivity, postprandial gut
      hormone response, lipid handling and adipocytokine profile in the following 4 groups:

        -  controlled acromegalic patients on LA-SMSA (group 1)

        -  controlled acromegalic patients on combination treatment of LA-SMSA and pegvisomant
           (group 2)

        -  acromegalic patients without need for medical therapy after surgery (group 3)

        -  healthy control subjects (group 4)

      Furthermore, a longitudinal exploration will be performed in uncontrolled acromegalic
      patients (i.e. patients with serum IGF-1 levels above age-specific thresholds and/or symptoms
      due to active acromegaly (excessive sweating , arthralgia)) on LA-SMSA monotherapy (group 5).
      In this group, insulin sensitivity, postprandial gut hormone response, lipid handling and
      adipocytokine profile will be explored before introducing pegvisomant and three months after
      normalisation of IGF-1 levels.

      The investigators hypothesize that lipid and glucose handling will be less efficient in the
      controlled acromegalic patients on LA-SMSA than in controlled patients on combination therapy
      or after surgery, and that there will be no difference in substrate metabolism between
      healthy controls and controlled acromegalic patients on combination treatment or after
      surgery. Further, they hypothesize that introducing pegvisomant in uncontrolled acromegalic
      patients will improve their postprandial lipid and glucose handling.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in insulin sensitivity</measure>
    <time_frame>before start of pegvisomant and 3 months after normalisation of IGF-1 after start of pegvisomant in group 5</time_frame>
    <description>Glucose disposal rate during last half hour of hyperinsulinemic-euglycemic clamp procedure, corrected for lean body mass (in µmol/min/kgLBM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>At enrollment in groups 1-4</time_frame>
    <description>Glucose disposal rate during last half hour of hyperinsulinemic-euglycemic clamp procedure, corrected for lean body mass (in µmol/min/kgLBM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting and postprandial glucose</measure>
    <time_frame>At enrollment in groups 1-4</time_frame>
    <description>Serum glucose levels during mixed-meal test (before and 10, 30, 60, 120, 180, 240, 300 minutes after ingestion of standard mixed-meal (bread, margarine, cheese and milk) providing a caloric content of 1000 kCal whereby 45% of the energy comes from fat, 36% from carbohydrates and 19% from proteins)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting and postprandial insulin</measure>
    <time_frame>At enrollment in groups 1-4</time_frame>
    <description>Insulin levels during standard mixed-meal test (cfr.supra)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting and postprandial gut hormone levels</measure>
    <time_frame>At enrollment in groups 1-4</time_frame>
    <description>Serum levels of gastric inhibitory polypeptide (GIP), ghrelin, peptide YY, pancreatic polypeptide, glucagon-like peptide 1 (GLP-1), oxyntomodulin and cholecystokinin before start during standard mixed-meal test (cfr.supra)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting adipokine levels</measure>
    <time_frame>At enrollment in group 1-4</time_frame>
    <description>Fasting serum levels of leptin, adiponectin and interleukin 6 (IL-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting lipid levels</measure>
    <time_frame>At enrollment in groups 1-4</time_frame>
    <description>Fasting serum levels of triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in fasting and postprandial glucose</measure>
    <time_frame>before start of pegvisomant and 3 months after normalisation of IGF-1 levels after start of pegvisomant in group 5</time_frame>
    <description>Serum glucose levels during mixed-meal test (before and 10, 30, 60, 120, 180, 240, 300 minutes after ingestion of standard mixed-meal (bread, margarine, cheese and milk) providing a caloric content of 1000 kCal whereby 45% of the energy comes from fat, 36% from carbohydrates and 19% from proteins)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in fasting and postprandial insulin levels</measure>
    <time_frame>before start of pegvisomant and 3 months after normalisation of IGF-1 levels after start of pegvisomant in group 5</time_frame>
    <description>Insulin levels during standard mixed-meal test (cfr.supra)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in fasting and postprandial gut hormone levels</measure>
    <time_frame>before start of pegvisomant and 3 months after normalisation of IGF-1 levels after start of pegvisomant in group 5</time_frame>
    <description>Serum levels of gastric inhibitory polypeptide (GIP), ghrelin, peptide YY, pancreatic polypeptide, glucagon-like peptide 1 (GLP-1), oxyntomodulin and cholecystokinin before start during standard mixed-meal test (cfr.supra)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in fasting adipokine levels</measure>
    <time_frame>before start of pegvisomant and 3 months after normalisation of IGF-1 levels after start of pegvisomant in group 5</time_frame>
    <description>Fasting serum levels of leptin, adiponectin and interleukin 6 (IL-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in fasting lipid levels</measure>
    <time_frame>before start of pegvisomant and 3 months after normalisation of IGF-1 levels after start of pegvisomant in group 5</time_frame>
    <description>Fasting serum levels of triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Resting energy expenditure</measure>
    <time_frame>At enrollment in group 1-4</time_frame>
    <description>Resting energy expenditure determined using indirect calorimetry</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>At enrollment in group 1-4</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Standing height</measure>
    <time_frame>At enrollment in group 1-4</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Waist and hip circumference</measure>
    <time_frame>At enrollment in group 1-4</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in resting energy expenditure</measure>
    <time_frame>before start of pegvisomant and 3 months after normalisation of IGF-1 levels after start of pegvisomant in group 5</time_frame>
    <description>Resting energy expenditure determined using indirect calorimetry</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight change</measure>
    <time_frame>before start of pegvisomant and 3 months after normalisation of IGF-1 levels after start of pegvisomant in group 5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in standing height</measure>
    <time_frame>before start of pegvisomant and 3 months after normalisation of IGF-1 levels after start of pegvisomant in group 5</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in waist and hip circumference</measure>
    <time_frame>before start of pegvisomant and 3 months after normalisation of IGF-1 levels after start of pegvisomant in group 5</time_frame>
  </other_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Controlled on LA-SMSA</arm_group_label>
    <description>Patients with controlled acromegaly on long-acting somatostatin analogs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlled on LA-SMSA and pegvisomant</arm_group_label>
    <description>Patients with controlled acromegaly on long-acting somatostatin analogs and pegvisomant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlled after surgery</arm_group_label>
    <description>Controlled acromegaly patients without need for medical therapy after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healhy controls</arm_group_label>
    <description>Healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uncontrolled on LA-SMSA</arm_group_label>
    <description>Patients with uncontrolled acromegaly (i.e. with serum IGF-1 levels above age-specific thresholds and/or symptoms due to active acromegaly (e.g. excessive sweating, arthralgia)) on LA-SMSA monotherapy in maximal dosage</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Groups 1-3 and 5: outpatient clinic attendants Group 4: recruted from community (by
        placard)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of acromegaly over 1 year ago, no changes in treatment schedule since at
             least 6 months (groups 1-3 and 5) OR healthy volunteer without diagnosis of acromegaly
             (group 4)

          -  Patient is willing to participate and has signed the informed consent

          -  Age &gt; 18 years and &lt; 80 years

          -  Body Mass Index 18-40 kg/m²

        Exclusion Criteria:

          -  Biochemistry: liver function tests &gt; 3x ULN; HbA1C &gt; 58 mmol/mol

          -  All untreated endocrine disorders including uncontrolled diabetes mellitus type 2
             (i.e. HbA1C &gt; 58 mmol/mol)

          -  Bariatric surgery; malabsorptive syndromes; hepatic or renal failure

          -  Current medication use: insulin, metformin, sulfonylurea, fibrates, incretin mimetics,
             dopamine agonists (for all but insulin, participation is allowed after a 2- week
             wash-out period)

          -  Abuse of alcohol or drugs

          -  Weight changes &gt; 10% of body weight during preceding 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy T'Sjoen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ghent University Hospital, Department of Endocrinology, 9K12IE</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf). 2003 Oct;59(4):492-9.</citation>
    <PMID>14510913</PMID>
  </reference>
  <reference>
    <citation>Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005 Oct;90(10):5684-91. Epub 2005 Aug 2.</citation>
    <PMID>16076947</PMID>
  </reference>
  <reference>
    <citation>Berg C, Petersenn S, Lahner H, Herrmann BL, Buchfelder M, Droste M, Stalla GK, Strasburger CJ, Roggenbuck U, Lehmann N, Moebus S, Jöckel KH, Möhlenkamp S, Erbel R, Saller B, Mann K; Investigative Group of the Heinz Nixdorf Recall Study and the German Pegvisomant Observational Study Board and Investigators. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab. 2010 Aug;95(8):3648-56. doi: 10.1210/jc.2009-2570. Epub 2010 May 12.</citation>
    <PMID>20463098</PMID>
  </reference>
  <reference>
    <citation>Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol. 2006 Mar;154(3):467-77.</citation>
    <PMID>16498061</PMID>
  </reference>
  <reference>
    <citation>De Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, Mazziotti G, Pontecorvi A, Giustina A. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary. 2007;10(3):227-32.</citation>
    <PMID>17484056</PMID>
  </reference>
  <reference>
    <citation>Freda PU, Reyes CM, Conwell IM, Sundeen RE, Wardlaw SL. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy. J Clin Endocrinol Metab. 2003 May;88(5):2037-44.</citation>
    <PMID>12727951</PMID>
  </reference>
  <reference>
    <citation>Kim SK, Suh S, Lee JI, Hur KY, Chung JH, Lee MK, Min YK, Kim JH, Kim JH, Kim KW. The ability of β-cells to compensate for insulin resistance is restored with a reduction in excess growth hormone in Korean acromegalic patients. J Korean Med Sci. 2012 Feb;27(2):177-83. doi: 10.3346/jkms.2012.27.2.177. Epub 2012 Jan 27.</citation>
    <PMID>22323865</PMID>
  </reference>
  <reference>
    <citation>Kozakowski J, Rabijewski M, Zgliczyński W. [Lowered ghrelin levels in acromegaly—normalization after treatment]. Endokrynol Pol. 2005 Nov-Dec;56(6):862-70. Polish.</citation>
    <PMID>16821203</PMID>
  </reference>
  <reference>
    <citation>Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009 May;94(5):1500-8. doi: 10.1210/jc.2008-2332. Epub 2009 Feb 10. Review.</citation>
    <PMID>19208728</PMID>
  </reference>
  <reference>
    <citation>Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009 Apr;30(2):152-77. doi: 10.1210/er.2008-0027. Epub 2009 Feb 24. Review.</citation>
    <PMID>19240267</PMID>
  </reference>
  <reference>
    <citation>Moller L, Norrelund H, Jessen N, Flyvbjerg A, Pedersen SB, Gaylinn BD, Liu J, Thorner MO, Moller N, Lunde Jorgensen JO. Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects. J Clin Endocrinol Metab. 2009 Nov;94(11):4524-32. doi: 10.1210/jc.2009-0381. Epub 2009 Oct 9.</citation>
    <PMID>19820031</PMID>
  </reference>
  <reference>
    <citation>Neggers SJ, Kopchick JJ, Jørgensen JO, van der Lely AJ. Hypothesis: Extra-hepatic acromegaly: a new paradigm? Eur J Endocrinol. 2011 Jan;164(1):11-6. doi: 10.1530/EJE-10-0969. Epub 2010 Nov 2.</citation>
    <PMID>21045065</PMID>
  </reference>
  <reference>
    <citation>Peracchi M, Porretti S, Gebbia C, Pagliari C, Bucciarelli P, Epaminonda P, Manenti S, Arosio M. Increased glucose-dependent insulinotropic polypeptide (GIP) secretion in acromegaly. Eur J Endocrinol. 2001 Jul;145(1):R1-4.</citation>
    <PMID>11415859</PMID>
  </reference>
  <reference>
    <citation>Pierluissi J, de Pierluissi RM. Effect of glucose-dependent insulinotropic polypeptide (GIP) on insulin response to glucose in acromegalics. Acta Cient Venez. 1995;46(2):89-96.</citation>
    <PMID>9279024</PMID>
  </reference>
  <reference>
    <citation>Plöckinger U, Holst JJ, Messerschmidt D, Hopfenmüller W, Quabbe HJ. Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects. Eur J Endocrinol. 1999 Jun;140(6):538-44.</citation>
    <PMID>10377503</PMID>
  </reference>
  <reference>
    <citation>Velasquez-Mieyer PA, Umpierrez GE, Lustig RH, Cashion AK, Cowan PA, Christensen M, Spencer KA, Burghen GA. Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults. Int J Obes Relat Metab Disord. 2004 Feb;28(2):330-3.</citation>
    <PMID>14708034</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <last_update_submitted>December 7, 2016</last_update_submitted>
  <last_update_submitted_qc>December 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acromegaly</keyword>
  <keyword>Acromegaly treatment</keyword>
  <keyword>Long-acting somatostatin analogs</keyword>
  <keyword>Pegvisomant</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Gut hormones</keyword>
  <keyword>Lipid metabolism</keyword>
  <keyword>Adipokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

